Monday snips | Biotech Message Board Posts
  • Limited Premium Membership Offer: Lifetime @ $399 5-yr @ $199 2-yr @ $99


  • Membership Drive Update:
     Thanks to continued support from loyal customers like you, we're now up to 24% of our "pandemic survival" goal! 

Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  33217 of 34575  at  7/6/2020 7:15:44 AM  by

minxmrphd


Monday snips

 

$DTIL Regains Rights to In Vivo Hepatitis B Virus Program from $GILD

$REGN Announces Start of REGN-COV2 Phase 3 #COVID19 Prevention Trial in Collaboration with NIAID

$VIR 6.2M shares offering

$AKRO - Akero Therapeutics readies equity offering

$BLU Primary endpoint of placebo-adjusted reduction in awake cough frequency did not reach statistical significance

$CYDY risk/reward ratio has worsened palpably - HCW. Downgraded to Neutral from Buy.

$GILD European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury (remdesivir) for the Treatment of #COVID19

 

$MYL Secures Regulatory Approval for #Remdesivir 100 mg/vial in India for Restricted Emergency Use in #COVID19 Patients. $GILD

$OBSV Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2 of Yselty for the Treatment of Uterine Fibroids



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 17     Views: 238
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
33218 Re: Monday snips minxmrphd 14 7/6/2020 7:41:38 AM






Financial Market Data provided by
.


Loading...